Characterization of “in vitro” models of Parkinson's disease: a rescue effect of phosphatidylcholine

GATTI, S; DIAZ REYES, M; SALVADOR, G; BIANCHIO, C

Mendoza

Congreso; Congreso. LVIII Annual Meeting of the Argentine Society for Biochemistry and Molecular Biology Research (SAIB); 2022

Parkinson´s disease is the second most prevalent neurodegenerative disease in the world. It is caused by death of dopaminergicneurons in the “substantia nigra”, and characterized by the aggregation of the α-Synuclein protein in cytoplasmic inclusions calledLewy bodies, mitochondrial dysfunction and generation of reactive oxygen species. The present study aimed to establish "in vitro´´models of Parkinson´s disease. For this, SHSY5Y neuroblastoma cells were transfected with plasmids designed to overexpress thewild type α-Synuclein or the mutant A53T (mutation of adenine by threonine in amino acid 53 that increases protein aggregation),or cells were treated with 6-hydroxydopamine, a drug that induces mitochondrial deficits and stimulates several pro-apoptosismolecular factors. To validate the models, survival was analyzed and cellular death was identified and quantified by biochemicaland morphological methods. We have previously demonstrated that liposomes of phosphatidylcholine exert a neuroprotective effectunder inflammatory conditions by increasing neuronal plasticity and differentiation. Thus, we evaluated the effect of thisphospholipid in the established models of Parkinson´s disease to further characterize its neuroprotective effect